Background
• Congenital Hyperinsulinism (CHI) can cause severe hypoglycaemia with consequent adverse neurodevelopment
• Continuous Glucagon Infusion (CGI) has been utilised to achieve glycaemic stability -its efficacy has not been systematically reported
Aims
• To review the efficacy of CGI and assess the complications associated with glucagon infusion
Methods
• A retrospective review was conducted, in a cohort of 31 children over a 5 year period
• The efficacy of CGI was reviewed by assessing the impact on the glucose infusion rate (GIR) within 48 hours of treatment
• Factors affecting severity of CHI: K-ATP channel gene mutations, diazoxide unresponsiveness, requirement for second-line treatment with octreotide and sub-total pancreatectomy were also assessed in relation to CGI
Results
• CGI in a dose of 5 mcg/kg/hour administered either intravenously (n=29) or subcutaneously (n=2) reduced GIR from a mean (interquartile range) of 15.9 (8.1) to 11.5 (4.9) mg/kg/minute. See Fig. 1 • Reduction independent of factors affecting the severity of CHI 
Conclusions
• CGI is effective in reducing GIR in patients with CHI in the short and long term management
• Generally safe, NME is a possible adverse event with CGI treatment
Complications
• 1 patient developed a necrolytic migratory erythema (NME) -Resolved once CGI discontinued. Refer to Fig. 2 • Crystallization of glucagon can lead to line obstruction, though not reported in this study 
